Condition: Autism Spectrum Disorder · Sponsor: Rossignol Medical Center
Multisite 14-week prospective double-blind placebo controlled parallel-group randomized clinical trial with 14-week open-label extension at the end of double-blind treatment phase for placebo subjects. Eligible subjects will be randomized within each site in 2:1 ratio to receive either TB006 or placebo treatment.
This description comes directly from the study's public registry record.
Alina Espinoza · 844-ADTF-Research · info@autismdiscovery.org
Always discuss trial participation with your own doctor first.
| Rossignol Medical Center | Phoenix, Arizona, United States | Recruiting |
| Rossignol Medical Center | Aliso Viejo, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06500637